title: Blinatumomab may induce graft versus host leukemia in patients with pre-B ALL relapsing after hematopoietic stem cell transplant.
abstract: Blinatumomab, a bispecific T-cell engager monoclonal antibody used to manage Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) can be used to treat patients by inducing graft versus leukemia reaction post allogeneic hematopoietic stem cell transplantation, a feature which it was post allogeneic bone marrow transplantation, a feature which this drug was not aimed to do.
authors.affiliation: Department of Internal medicine Division of Hematology/Bone Marrow Transplantation University of Kentucky Lexington Kentucky.
authors.forename: Muhammad Waqas
authors.initials: MW
authors.lastname: Khan
authors.affiliation: Department of Internal medicine Division of Hematology/Bone Marrow Transplantation University of Kentucky Lexington Kentucky.
authors.forename: Zartash
authors.initials: Z
authors.lastname: Gul
keywords: BiTe antibody in ALL; blinatumomab in pre‐B ALL; post transplant ALL management; refractory ALL treatment